EDITORIAL: The introduction of a centralised track-and-trace system for pharmaceutical products in Pakistan marks a significant step towards protecting public health. The Drug Regulatory Authority of Pakistan (Drap) deserves recognition for finally making the system operational after years of delays. First proposed in 2015 and approved by the federal cabinet in 2017, its delayed implementation underscores the need to overcome bureaucratic hurdles, particularly when public health is at stake.
The initiative, which enables consumers to verify the authenticity and prices of medicines through the Mehfooz Dawa application, has the potential to enhance transparency, strengthen regulatory oversight and protect patients from counterfeit and substandard drugs.
For years, counterfeit, expired and improperly stored medicines have posed a serious threat to public health. Patients using such products may suffer complications, experience treatment failure or lose confidence in the healthcare system. The problem is particularly concerning for people with chronic illnesses who depend on regular medication. Moreover, the sale of medicines at inflated prices places an additional financial burden on families already struggling with rising healthcare costs. A system that provides information on both the authenticity and prices of medicines can, therefore, serve the dual purpose of protecting patients and discouraging exploitative commercial practices.
The introduction of a two-dimensional (2D) barcode on medicine packaging offers a practical means of addressing these concerns. By scanning the barcode with a smartphone, consumers can now verify the authenticity of medicines. At the same time, regulatory authorities can trace pharmaceutical products throughout the supply chain, making it easier to identify irregularities and arrange timely recalls in the event of quality concerns or complaints.
However, the launch of the application should not be regarded as an end in itself. Its effectiveness will depend on proper implementation, public awareness and consistent enforcement. Many people, particularly in rural areas, may not own smartphones or be familiar with the application. Alternative arrangements should be available for consumers without smartphones so that they are not deprived of the benefits of this initiative. Drap should also undertake nationwide awareness campaigns through the media and healthcare services, encouraging people to use the facility to verify their medicines.
Equally important is ensuring that pharmaceutical manufacturers, distributors, wholesalers, and retailers comply fully with the barcode requirements. Regular inspections, strict penalties for violations and an accessible mechanism for reporting complaints are essential to making the system effective. The relevant authorities must ensure that the system is not merely operational on paper but functions effectively at every stage of the pharmaceutical supply chain.
The Mehfooz Dawa application is a welcome beginning, but its success will ultimately be judged by whether it helps ensure that every Pakistani, regardless of income or location, has access to genuine, safe and reasonably priced medicines.
Copyright Business Recorder, 2026
Comments